Fundraising Fox
/People
Sign in

Rob Readnour

Investor

Managing Director at Mountain Group Capital · Board director at AN2 Therapeutics

Nashville, Tennessee

Writes $100K – $5M checks · typically $1.5M

Find your path to Rob

131 people in our graph share verified history with Rob — schools, employers, funds. One of them is your warm intro.

Ramin KarimpourunlockedRob: together at Targan (2019–2026)
×6Rob: together at Elanco
Rob: together at Southeast Missouri State University
×4Rob: together at AN2 Therapeutics

About

Managing Director focused on animal health and drug development. Spent nearly 30 years at Elanco Animal Health leading R&D strategy and product commercialization; holds a PhD in Analytical Chemistry.

Board director at AN2 Therapeutics

Intro paths

→

In turn, Rob can intro founders to AN2 Therapeutics's investors below.

AN2 Therapeutics's investors · 7

Adjuvant CapitalNew York · $10M – $25M checks · since 2026BioRock VenturesSan Francisco · since 2026Biotechnology Value FundSan Francisco · since 2026Flucas VenturesJupiter · $100K – $5M checks · since 2026Hatteras Venture PartnersResearch Triangle · $500K – $4M checks · since 2026Mountain Group CapitalNashville · since 2026RA CapitalBoston · since 2026

Co-founders at AN2 Therapeutics

JS
Joseph S. ZakrzewskiCo-Founder & Director
EEEric Easom
Eric EasomCo-Founder, President & CEO
GH
George H. TalbotCo-Founder & Senior Clinical Advisor
MR
Michael R.K. (Dickon) AlleyCo-Founder, SVP Research Fellow, Head of Biology

Experience

  1. Mountain Group PartnersManaging Directorcurrent2018 — presentGreater Nashville Area, TN
  2. Advanced Animal DiagnosticsDirectorcurrent2021 — presentRaleigh, North Carolina, United States
  3. TARGAN Inc.Directorcurrent2019 — presentRaleigh-Durham, North Carolina Area
  4. ElancoSenior Advisor and Chief Scientific Officer - Elanco Alternative Innovation2017 — 2018Greenfield Indiana
  5. Elanco Animal HealthSenior Director of Product Development, Elanco Animal Health1990 — 2017

Skills & more

Analytical Chemistry32Chemistry24FDA10Lifesciences5Product Development23Regulatory Affairs9Drug Development61Commercialization25GMP7Veterinary Medicine4Drug Discovery7Immunology3
+12 moreTechnology TransferValidationBiotechnologyR&DVaccinesRegulatory SubmissionsBiopharmaceuticalsClinical TrialsLeadershipManagementPharmaceutical IndustryOncology

Languages English

From Rob's professional profile.

Investments

Per curated public sources.

Colleagues at Mountain Group Capital

Byron Smith
Managing Director at Mountain Group Capital
Chapman Varnell
Associate at Mountain Group Capital
Gerard Franks
Director at Mountain Group Capital
Jack Slaughter
Principal at Mountain Group Capital
Joe Cook III
Managing Director at Mountain Group Capital
Joe Cook Jr
Managing Director at Mountain Group Capital
Lincoln Chambers
Associate at Mountain Group Capital
Rana Al Shehri
Operations Coordinator at Flat6Labs

Network1

Byron Smith
Managing Director at Mountain Group Capital

Investors connected to Rob in public investor directories — a warm-intro map.

Frequently asked questions

Who is Rob Readnour?
Managing Director focused on animal health and drug development. Spent nearly 30 years at Elanco Animal Health leading R&D strategy and product commercialization; holds a PhD in Analytical Chemistry.
Where does Rob Readnour work?
Rob Readnour is Managing Director at Mountain Group Capital and Board director at AN2 Therapeutics.
What check size does Rob Readnour write?
Rob Readnour typically writes checks of $100K – $5M.
What companies has Rob Readnour invested in?
Investments tracked here include Advanced Animal Diagnostics, AN2 Therapeutics, Targan, Verility.
Where did Rob Readnour go to school?
Rob Readnour studied at University of Illinois Urbana-Champaign (PhD, Analytical Chemistry); Southeast Missouri State University (B.S., Chemistry).

Same school

Shared employers